Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Eugene Braunwald, M.D.

Co-Author

This page shows the publications co-authored by Eugene Braunwald and Benjamin Scirica.
Connection Strength

9.044
  1. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. JAMA Cardiol. 2018 02 01; 3(2):155-163.
    View in: PubMed
    Score: 0.766
  2. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010 Aug; 31(16):1993-2005.
    View in: PubMed
    Score: 0.452
  3. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2009 Apr 21; 53(16):1411-21.
    View in: PubMed
    Score: 0.417
  4. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007 Oct 09; 116(15):1647-52.
    View in: PubMed
    Score: 0.372
  5. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.
    View in: PubMed
    Score: 0.367
  6. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis. 2006 Oct; 22(2):95-102.
    View in: PubMed
    Score: 0.349
  7. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.
    View in: PubMed
    Score: 0.342
  8. Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Crit Pathw Cardiol. 2002 Sep; 1(3):150-8.
    View in: PubMed
    Score: 0.263
  9. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 01; 90(3):303-5.
    View in: PubMed
    Score: 0.262
  10. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. J Am Coll Cardiol. 2021 04 13; 77(14):1837-1840.
    View in: PubMed
    Score: 0.239
  11. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020 03 17; 75(10):1095-1106.
    View in: PubMed
    Score: 0.222
  12. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clin Chem. 2019 06; 65(6):781-790.
    View in: PubMed
    Score: 0.208
  13. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes Care. 2018 03; 41(3):577-585.
    View in: PubMed
    Score: 0.189
  14. Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes-Reply. JAMA Cardiol. 2017 07 01; 2(7):821.
    View in: PubMed
    Score: 0.184
  15. Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 Dec 01; 1(9):989-998.
    View in: PubMed
    Score: 0.177
  16. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care. 2016 Aug; 39(8):1329-37.
    View in: PubMed
    Score: 0.170
  17. Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation. 2015 Aug 11; 132(6):e121-2.
    View in: PubMed
    Score: 0.161
  18. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Europace. 2015 Jan; 17(1):32-7.
    View in: PubMed
    Score: 0.151
  19. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28; 130(18):1579-88.
    View in: PubMed
    Score: 0.151
  20. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med. 2014 01 30; 370(5):483-4.
    View in: PubMed
    Score: 0.145
  21. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 03; 369(14):1317-26.
    View in: PubMed
    Score: 0.141
  22. Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial. Clin Chem. 2013 Jun; 59(6):959-67.
    View in: PubMed
    Score: 0.137
  23. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012 Oct 13; 380(9850):1317-24.
    View in: PubMed
    Score: 0.131
  24. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011 Nov; 162(5):818-825.e6.
    View in: PubMed
    Score: 0.124
  25. Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial). Am J Cardiol. 2011 Nov 15; 108(10):1373-81.
    View in: PubMed
    Score: 0.123
  26. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J. 2011 Jun; 32(11):1390-7.
    View in: PubMed
    Score: 0.118
  27. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011 Mar; 32(6):697-705.
    View in: PubMed
    Score: 0.117
  28. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010 Aug 03; 122(5):455-62.
    View in: PubMed
    Score: 0.114
  29. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010 Mar 23; 55(12):1189-1196.
    View in: PubMed
    Score: 0.111
  30. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.109
  31. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009 Jun 02; 119(21):2758-64.
    View in: PubMed
    Score: 0.105
  32. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73.
    View in: PubMed
    Score: 0.102
  33. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7.
    View in: PubMed
    Score: 0.093
  34. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2326-31.
    View in: PubMed
    Score: 0.085
  35. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002 Oct 15; 90(8):821-6.
    View in: PubMed
    Score: 0.066
  36. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 2021 Nov; 44(11):2573-2581.
    View in: PubMed
    Score: 0.062
  37. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16; 143(7):685-695.
    View in: PubMed
    Score: 0.059
  38. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med. 2021 02; 14(1):e003006.
    View in: PubMed
    Score: 0.059
  39. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 Feb 02; 143(5):470-478.
    View in: PubMed
    Score: 0.058
  40. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 11 05; 140(19):1569-1577.
    View in: PubMed
    Score: 0.053
  41. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation. 2019 09 17; 140(12):1004-1014.
    View in: PubMed
    Score: 0.053
  42. Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes. J Am Heart Assoc. 2019 05 07; 8(9):e011444.
    View in: PubMed
    Score: 0.052
  43. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019 01 01; 123(1):145-152.
    View in: PubMed
    Score: 0.050
  44. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol. 2017 01; 10(1).
    View in: PubMed
    Score: 0.044
  45. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clin Chem. 2017 Jan; 63(1):307-315.
    View in: PubMed
    Score: 0.044
  46. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 10 24; 9(20):2157-2164.
    View in: PubMed
    Score: 0.044
  47. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2017 Jan; 40(1):69-76.
    View in: PubMed
    Score: 0.044
  48. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. Eur Heart J Acute Cardiovasc Care. 2017 Mar; 6(2):164-172.
    View in: PubMed
    Score: 0.044
  49. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation. 2016 Jul 26; 134(4):304-13.
    View in: PubMed
    Score: 0.043
  50. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 07 19; 68(3):322-323.
    View in: PubMed
    Score: 0.043
  51. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50. J Am Heart Assoc. 2016 07 18; 5(7).
    View in: PubMed
    Score: 0.043
  52. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation. 2016 Mar 08; 133(10):997-1005.
    View in: PubMed
    Score: 0.042
  53. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). Am J Cardiol. 2016 Apr 01; 117(7):1055-8.
    View in: PubMed
    Score: 0.042
  54. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. Am J Med. 2016 Mar; 129(3):340.e1-8.
    View in: PubMed
    Score: 0.041
  55. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. Circulation. 2015 Nov 17; 132(20):1871-9.
    View in: PubMed
    Score: 0.041
  56. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19; 4(3):e001505.
    View in: PubMed
    Score: 0.039
  57. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015 Jun; 38(6):1145-53.
    View in: PubMed
    Score: 0.039
  58. Impact of treatment with saxagliptin on glycaemic stability and ß-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab. 2015 May; 17(5):487-94.
    View in: PubMed
    Score: 0.039
  59. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015 Mar 24; 131(12):1047-53.
    View in: PubMed
    Score: 0.039
  60. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015 Apr; 38(4):696-705.
    View in: PubMed
    Score: 0.039
  61. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2309-17.
    View in: PubMed
    Score: 0.038
  62. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2318-26.
    View in: PubMed
    Score: 0.038
  63. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol. 2014 Apr 29; 63(16):1644-53.
    View in: PubMed
    Score: 0.036
  64. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev. 2013 Jul; 29(5):417-26.
    View in: PubMed
    Score: 0.035
  65. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
    View in: PubMed
    Score: 0.034
  66. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar; 44(3):691-8.
    View in: PubMed
    Score: 0.034
  67. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2012 Jul 24; 60(4):332-8.
    View in: PubMed
    Score: 0.033
  68. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clin Cardiol. 2012 Dec; 35(12):722-9.
    View in: PubMed
    Score: 0.033
  69. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12; 366(15):1404-13.
    View in: PubMed
    Score: 0.032
  70. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart. 2012 May; 98(10):786-91.
    View in: PubMed
    Score: 0.032
  71. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012 Jan; 58(1):257-66.
    View in: PubMed
    Score: 0.031
  72. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J. 2010 Jun; 159(6):964-971.e1.
    View in: PubMed
    Score: 0.028
  73. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010 May 11; 55(19):2118-24.
    View in: PubMed
    Score: 0.028
  74. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009 Sep; 158(3):335-341.e3.
    View in: PubMed
    Score: 0.027
  75. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009 Apr 28; 53(17):1510-6.
    View in: PubMed
    Score: 0.026
  76. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009 Apr 21; 119(15):2032-9.
    View in: PubMed
    Score: 0.026
  77. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008 Nov; 1(2):107-15.
    View in: PubMed
    Score: 0.025
  78. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008 Apr 19; 371(9621):1353-63.
    View in: PubMed
    Score: 0.024
  79. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25; 297(16):1775-83.
    View in: PubMed
    Score: 0.023
  80. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). Am Heart J. 2006 Oct; 152(4):756-61.
    View in: PubMed
    Score: 0.022
  81. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006 Jun; 151(6):1186.e1-9.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.